NRAS and melanoma: Resistance biomarkers primarily consisted of KRAS mutations, which confer resistance to anti-EGFR therapies, occurring in 89.5% of PDAC cases, and NRAS mutations in the melanoma datasets (Figure 2C, Supplementary Figure S2B, available at https://doi.org/10.1016/j.esmoop.2022.100540).